Acutaas Chemicals Ltd Q4 FY26 Earnings Analysis
Published 17 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹26.9K Cr
Price
₹3,236
Market Cap
₹26.9K Cr
P/E Ratio
69.6
Earnings Summary
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
📊 Revenue & Sales Performance
- →The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17).
- →Growth drivers for FY '27 and beyond include:
- → - Electrolyte additive division (battery chemicals).
- → - Pharma intermediate business, which is the biggest growth engine.
- → - Semiconductor chemical business, starting with BFC and Indichem JV in 2-3 years (Page 15).
- →CDMO business has a long-term 10-year contract ensuring visibility and revenue stability; with multiple new products in validation/commercial phases (Page 14-15).
- →Electrolyte additive capacity expansion underway; capacity of 2,000 MT indicates significant revenue potential (Page 14).
- →Seasonality effect expected but new contracts like Fermion ramp-up may reduce Q1 dips (Page 17).
- →New versatile R&D centre and infrastructure expansions underway to support growth over next 5-10 years (Page 6).
- →Overall, 25% revenue growth is expected until at least FY '28, supported by multiple growth engines and product portfolio upgrades.
📈 Profitability & Margins
- →Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
- →Growth driven by three engines: pharma intermediates (including CDMO), electrolyte additive (battery chemicals), and semiconductor business (including BFC and Indichem JV).
- →EBITDA margins expected to be maintained at FY '26 levels (~42% quarterly / ~35% annual), supported by product mix and operating leverage.
- →CDMO business anticipated to contribute significantly, with new validated products having peak revenues of INR 50-100 crores each.
- →Capex of ~INR 100 crores planned for FY '27, with further R&D center capex to be finalized, supporting innovation and growth beyond FY '28.
- →BFC business recovering strongly, contributing to specialty chemicals margin and growth.
- →Long term growth supported by strategic portfolio upgrade and expansion into high value products, semiconductor, battery chemicals, and pharma intermediates sectors.
🏗️ Capital Expenditure Plans
- →FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
- →Spillover capex of around INR50 crores related to electrolyte additive and pilot plant expected in FY '27.
- →FY '27 planned capex around INR90 crores (INR50 crores spillover + INR40 crores maintenance), excluding new R&D center costs.
- →New versatile R&D center planned with ~10x capacity expansion, covering pharmaceuticals, battery chemicals, semiconductors, electronics, cosmetics, and more.
- →Continued investment in the South Korea joint venture Indichem with INR190 crores invested in FY '26; plant commissioning expected in second half of calendar 2026.
- →Evaluating land acquisition for further infrastructure development to support long-term growth.
- →Strategic migration from commodity chemical products to higher-value differentiated products ongoing.
💰 Fundraising & Capital Structure
- For FY '27, Acutaas Chemicals Limited plans capex around INR 100 crores, including INR 50 crores spillover from FY '26 and approximately INR 40 crores maintenance capex, plus planned capex on the new R&D centre (exact figures pending finalization).
- There is no explicit mention of new fundraising through debt or equity in the provided transcripts for the current or near future.
- Management emphasizes intelligent investment for growth, such as in R&D and capacity expansions, but has not indicated intentions to raise external capital via debt or equity in this call.
- Past investments, such as INR 190 crores in Indichem JV, have been funded internally.
- Investor questions about capex and expansion were answered without reference to new fundraising plans.
Thus, based on the available information, no current or immediate future plans for fundraising through debt or equity have been disclosed.
📋 Order Book & Pipeline
- →For the CDMO business, Acutaas Chemicals has a confirmed long-term supply contract in place for 10 years with their first customer, providing good visibility and backlog.
- →The electrolyte additive segment has customer contracts already signed, covering the full 2,000 metric ton capacity for at least the next 3 years.
- →There are four additional CDMO products beyond the Fermion contract, validated and awaiting regulatory approval, with each expected to have a revenue potential of INR 50-100 crores at peak levels.
- →The production for these CDMO products has started, and commercial revenues are expected to ramp up in FY'27 with meaningful contributions from both CDMO and electrolyte additive businesses.
- →The company maintains a healthy and secured order book backed by contracts for multiple years across their CDMO and specialty chemical verticals.
Key Metrics
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q4 FY26 results?
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.